Suppliers / Dr. Reddy's Laboratories

Dr. Reddy's Laboratories

India RDY 62 employees 5 duplicate records merged Updated 9 July 2026

Dr. Reddy's Laboratories is an API and finished-dose manufacturer based in India. It holds 270 active US drug master files and 90 valid CEPs. Its filings concentrate with US FDA, Health Canada and MHRA (UK). Its GMP standing is certified by EMA, US FDA and CDSCO (India), among 9 authorities. Its most recent recorded inspection, by US FDA, closed on 14 November 2025 as NAI. Customs aggregates show $72.3M of exports covering 894 molecules to 64 destinations in 2025.

270
active US DMFs
90
valid CEPs
12
registered plants 6 with an FDA FEI number
1,890
filings across 26 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
6 of 6 confirmed
Inspections
4 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 14 November 2025 NAI US FDA
  • 18 July 2025 VAI US FDA
  • 24 May 2025 VAI US FDA
  • 19 November 2024 VAI US FDA
  • 20 September 2024 NAI US FDA
  • 7 June 2024 VAI US FDA
  • 17 May 2024 VAI US FDA
  • 8 December 2023 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Hyderabad, United Arab Emirates Not on file
Visakhapatnam, United Arab Emirates Not on file
Basel, Switzerland Not on file
Telangana, Colombia Not on file
BEVERLEY, United Kingdom Not on file
Srikakulam, India 3012414462

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Atorvastatin SFDA (Saudi Arabia), US FDA 9
Omeprazole EDQM, US FDA 8
Naproxen EDQM, US FDA 7
Empagliflozin SFDA (Saudi Arabia), US FDA 6
Ondansetron EDQM, SFDA (Saudi Arabia), US FDA 6
Sitagliptin EDQM, SFDA (Saudi Arabia), US FDA 6
Ciprofloxacin EDQM, SFDA (Saudi Arabia), US FDA 5
Clopidogrel EDQM, SFDA (Saudi Arabia), US FDA 5
Esomeprazole EDQM, US FDA 5
Sumatriptan EDQM, SFDA (Saudi Arabia), US FDA 5
Show all 30 molecules on file
Glimepiride EDQM, SFDA (Saudi Arabia), US FDA 4
Ketorolac EDQM, SFDA (Saudi Arabia), US FDA 4
Lenalidomide SFDA (Saudi Arabia), US FDA 4
Moxifloxacin EDQM, SFDA (Saudi Arabia), US FDA 4
Pantoprazole EDQM, SFDA (Saudi Arabia), US FDA 4
Pregabalin EDQM, SFDA (Saudi Arabia), US FDA 4
Rivastigmine EDQM, US FDA 4
Valsartan EDQM, SFDA (Saudi Arabia), US FDA 4
Voriconazole EDQM, US FDA 4
Amlodipine EDQM, SFDA (Saudi Arabia), US FDA 3
Atorvastatin Calcium EDQM 3
Cabozantinib US FDA 3
Capecitabine EDQM, SFDA (Saudi Arabia), US FDA 3
Cetirizine Dihydrochloride EDQM, SFDA (Saudi Arabia) 3
Dapagliflozin US FDA 3
Desloratadine EDQM, SFDA (Saudi Arabia), US FDA 3
Docetaxel EDQM, SFDA (Saudi Arabia), US FDA 3
Enalapril EDQM, SFDA (Saudi Arabia), US FDA 3
Escitalopram EDQM, SFDA (Saudi Arabia), US FDA 3
Finasteride EDQM, US FDA 3

Also appears on these molecule pages

Show 142 more molecule pages
Caffeine finished dose Capecitabine API Carvedilol API Celecoxib API Cetirizine API Chlorpromazine finished dose Ciclosporin finished dose Ciprofloxacin API Citalopram API Clarithromycin finished dose Clobetasol finished dose Clopidogrel API Codeine finished dose Dapagliflozin API Daptomycin finished dose Desloratadine API Desogestrel finished dose Desvenlafaxine finished dose Dexamethasone finished dose Dexlansoprazole API Dextromethorphan finished dose Diazepam finished dose Diltiazem finished dose Diphenhydramine finished dose Domperidone finished dose Doxazosin API Doxycycline finished dose Drospirenone finished dose Duloxetine API Dutasteride API Empagliflozin API Emtricitabine finished dose Enalapril API Ertapenem finished dose Erythromycin finished dose Escitalopram API Esomeprazole API Estradiol finished dose Ethinylestradiol finished dose Ezetimibe API Famotidine API Febuxostat API Fenofibrate finished dose Fexofenadine API Finasteride API Fluconazole API Fluoxetine API Formoterol finished dose Gatifloxacin API Gliclazide finished dose Glimepiride API Heparin finished dose Hydrochlorothiazide finished dose Hydroxyzine finished dose Ibandronic Acid API Ibuprofen finished dose Irbesartan API Itraconazole finished dose Ivermectin finished dose Ketorolac Tromethamine API Lacosamide finished dose Lamivudine finished dose Lamotrigine API Lansoprazole API Lenalidomide API Letrozole API Levetiracetam API Levocetirizine API Levodopa finished dose Levofloxacin API Levonorgestrel finished dose Lidocaine finished dose Linagliptin API Liraglutide API Loperamide finished dose Losartan API Memantine API Metformin finished dose Methylprednisolone finished dose Metoprolol API Minoxidil finished dose Mirabegron API Montelukast API Moxifloxacin API Mycophenolate Mofetil finished dose Naproxen API Nateglinide API Nicotine finished dose Nitrofurantoin finished dose Norethisterone API Nystatin finished dose Ofloxacin finished dose Olanzapine API Omeprazole API Ondansetron API Paclitaxel finished dose Pantoprazole API Paracetamol finished dose Permethrin API Phenylephrine finished dose Pioglitazone API Prednisone finished dose Pregabalin API Progesterone finished dose Propofol finished dose Pseudoephedrine finished dose Quetiapine API Ramipril API Ranitidine API Risperidone API Ritonavir API Rivaroxaban API Sacubitril API Saxagliptin API Semaglutide API Sertraline API Sildenafil API Simvastatin finished dose Sitagliptin API Solifenacin API Sumatriptan API Tacrolimus finished dose Tadalafil API Tamoxifen finished dose Telmisartan API Tenofovir Disoproxil finished dose Terbinafine API Terbutaline finished dose Testosterone API Ticagrelor API Timolol finished dose Tizanidine API Tobramycin finished dose Tolvaptan finished dose Topiramate API Trimethoprim finished dose Valsartan API Venlafaxine API Vigabatrin finished dose Vildagliptin finished dose Zolmitriptan API Zolpidem API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 691 10
Health Canada 207 None
MHRA (UK) 185 1
SAHPRA (ZA) 177 None
EMA 112 13
CDSCO (India) 91 8
MFDS (Korea) None 6
ANVISA (Brazil) None 6
GOSPHARMNADZOR (BY) None 1
EAEU_EEC None 1
INVIMA (CO) None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $20.1M 49
2025 $3.8B $72.3M 64
2024 $3.4B Not reported Not reported
2023 $3.0B Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Dr. Reddy's Laboratories comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 50 active litigation matters are on record.
  • The most recent inspection outcome was NAI, on 14 November 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts
Company filings
Revenue as reported